Could astrocytes be the primary target of an offending agent causing the primary degenerative diseases of the human central nervous system? A hypothesis

Medical Hypotheses

Volumn 84, Issue 5, 2015, Pages 481-489

  Sica, Roberto E ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; ARTICLE; ASTROCYTE; BRAIN REGION; CELL DAMAGE; CELL FUNCTION; CELL METABOLISM; CELL POPULATION; CELL STRUCTURE; DEGENERATIVE DISEASE; GAP JUNCTION; HUMAN; HYPOTHESIS; MEMBRANE POTENTIAL; NERVE CELL PLASTICITY; PROTEIN STRUCTURE; SOMATIC CELL GENETICS; TARGET CELL; BIOLOGICAL MODEL; METABOLISM; NERVE CELL; NEURODEGENERATIVE DISEASES; PATHOPHYSIOLOGY; PHYSIOLOGY;

GAP JUNCTION PROTEIN;

APOPTOSIS; ASTROCYTES; CONNEXINS; GAP JUNCTIONS; HUMANS; MODELS, NEUROLOGICAL; NEURODEGENERATIVE DISEASES; NEURONS;

EID: 84925705269     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2015.02.004     Document Type: Article

References (89)

1. Cooper-Knock J., Shaw P.J., Kirgby J. The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype. Acta Neuropathol 2014, 127:333-345.
2. Kierdaszuk B., Berdynski M., Zekanowski C., Kaminska A. TDP-43 proteinopathies - from frontotemporal lobar degeneration to inclusion body myositis. Neurol Neurochir Pol 2012, 46:384-391.
3. Gendron T.F., Rademakers R., Petrucelli L. TARDBP mutation analysis in TDP-43 proteinopathies and deciphering the toxicity of mutant TDP-43. J Alzheimer's Dis 2013, 33(Supp 1):S35-S45.
4. Hughes A.C., Mort M., Elliston L., et al. Identification of novel alternative splicing events in the huntingtin gene and assessment of the functional consequences using structural protein homology modelling. J Mol Biol 2014, 426:1428-1438.
5. Shahaduzzaman M., Acosta S., Bickford P.C., Borlongan C.V. αSynuclein is a pathological link and therapeutic target for Parkinson's disease and traumatic brain injury. Med Hypotheses 2013, 81:675-680.
6. Deng H.X., Chen W., Hong S.T., et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 2011, 477:211-215.
7. Williams K.L., Warraich S.T., Yang S., et al. UBQLN2/ubiquilin 2 mutation and pathology in familial amyotrophic lateral sclerosis. Neurobiol Aging 2012, 33:2527-2532.
8. Korac J., Schaeffer V., Kovacevic I., et al. Ubiquitin-independent function of optineurin in autophagic clearance of protein aggregates. J Cell Sci 2013, 15:580-592.
9. Maruyama H., Morino H., Ito H., et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010, 465:223-226.
10. Wild P., Farhan H., McEwan D.G., et al. Phosphorylation of the autophagy receptor optineurin restricts Salmonella growth. Science 2011, 333:228-233.
11. Navarrete M., Araque A. The Cajal school and the physiological role of astrocytes: a way of thinking. Front Neuroanat 2014, 8:33. eCollection 2014. 10.3389/fnana.2014. 00033.
12. Araque A., Navarrete M. Glial cells in neuronal network function. Philos Trans R Soc Lond Biol Sci 2010, 365:2375-2381.
13. Rouach N., Tencé M., Glowinski J., Giaume C. Co-stimulation of N-methyl-d-aspartate and muscarinic neuronal receptors modulates gap junctions communication in striatal astrocytes. Proc Natl Acad Sci USA 2002, 99:1023-1028.
14. Kielian T., Esen N. Effects of neuroinflammation on glia-glia gap junctional intercellular communication: a perspective. Neurochem Int 2004, 45:429-436.
15. Kielian T. Glial connexins and gap junctions in CNS inflammation and disease. J Neurochem 2008, 106:1000-1016.
16. Hewett J.A. Determinants of regional and local diversity within the astroglial lineage of the normal central nervous system. J Neurochem 2009, 110:1717-1736.
17. Nag S. Morphology and properties of astrocytes. Methods Mol Biol 2011, 686:69-100.
18. Parpura V., Verkhratsky A. Homeostatic function of astrocytes: Ca (2+) and Na (+) signalling. Trans Neurosci 2012, 3:334-344.
19. Guthrie P.B., Knappenberer J., Segal M., Bennet M.V., Charles A.C., Kater S.B. ATP released from astrocytes mediates glia calcium waves. J Neurosci 1999, 15:520-528.
20. Araque A., Carmignoto G., Haydon P.G., Oljet S.H., Robitaille R., Volterra A. Gliotransmitters travel in time and space. Neuron 2014, 81:728-739.
21. Halassa M.M., Fellin T., Haydon P.G. The tripartite synapse: role for gliotransmission in health and disease. Trends Mol Med 2007, 13:54-63.
22. Pirttimaki T.M., Parri H.R. Astrocyte plasticity: implications for synaptic and neuronal activity. Neuroscientist 2013, 19:604-615.
23. Sidoryk-Wegrzynowicz M., Wegrzinowicz M., Lee E., Bowman A.B., Aschner M. Role of astrocytes in brain function and disease. Toxicol Pathol 2011, 39:115-123.
24. + and astrocyte signalling via connexin and pannexin channels. Neurochem Res 2012, 37:2310-2316.
25. Simard M., Arcino G., Takano T., Liu Q.S., Nedergaard M. Signaling at the gliovascular interface. J Neurosci 2003, 23:9254-9262.
26. Kimelberg H.K. Functions of mature mammalian astrocytes: a current view. Neuroscientist 2010, 16:79-106.
27. Schaeffer V., Meyer L., Patte-Mensah C., Mensah-Nyagan A.G. Progress in dorsal root gangli neurosteroidogenic activity: basic evidence and pathophysiological correlation. Prog Neurobiol 2010, 92:33-41.
28. Sica R.E. Is Amyotrophic lateral sclerosis a primary astrocytic disease?. Med Hypotheses 2012, 79:819-822.
29. Orellana J.A., Martinez A.D., Retamal M.A. Gap junction channels and hemichannels in the CNS: regulation by signaling molecules. Neuropharmacology 2013, 75:567-582.
30. Zhou J.Z., Jiang J.X. Gap junction and hemichannel-independent actions of connexins on cell and tissue functions-an update. FEBS Lett 2014, 588:1186-1192.
31. Orellana J.A., Froger N., Ezan P., et al. ATP and glutamate released via astroglial connexin 43 hemichannels mediate neuronal death through activation of pannexin 1 hemichannels. J Neurochem 2011, 118:826-840.
32. Orellana J.A., Figueroa X.P., Sachez H.A., Contreras-Duarte S., Velarde V., Saez J.C. Hemichannels in the neurovascular unit and white matter under normal and inflamed conditions. CNS Neurol Disord: Drug Targets 2011, 10:404-414.
33. Iwabuchi S., Kawahara K. Functional significance of the negative feed-back regulation of ATP release via pannexin-1 hemichannels under ischemic stress in astrocytes. Neurochem Int 2011, 58:376-384.
34. Nakase T., Sohl G., Theis M., Willecker K., Naus C.C. Increased apoptosis and inflammation after focal brain ischemia in mice lacking connexin 43 in astrocytes. Am J Pathol 2004, 164:2067-2075.
35. Rouach N., Koulakoff A., Giaume C. Neurons set the tone of gap junctional communication in astrocytic networks. Neurochem Int 2004, 45:265-272.
36. Kimelberg H.K. Functions of mature mammalian astrocytes: a current view. Neuroscentist 2010, 16:79-106.
37. Saikali P., Cayrol R., Vincent T. Anti-aquoporin 4 auto antibodies orchestrate the pathogenesis in neuromyelitis optica. Autoinmmun Rev 2009, 9:132-135.
38. Lucchinetti C.F., Guo Y., Popesku B.F., Fujihara K., Itoyama Y., Misu T. The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol 2014, 24:83-97.
39. Wrzos C., Winkler A., Metz I., et al. Early loss of oligodendrocytes in human and experimental neuromyelitis optica lesions. Acta Neuropathol 2014, 127:238-523.
40. Nualart-Marti A., Solsona C., Fields R.D. Gap junction communication in myelinating glia. Biochim Biophys Acta 2013, 1828:69-78.
41. Nedergaard M. Direct signalling from astrocytes to neurons in cultures of mammalian brain cells. Science 1994, 263:1768-1771.
42. Burda J.E., Sofroniew M.V. Reactive gliosis and multicellular response to CNS damage and disease. Neuron 2014, 81:229-248.
43. Khandelwal P.J., Herman A.M., Moussa C.E. Inflammation in the early stages of neurodegenerative pathology. J Neuroinmmunol 2011, 238:1-11.
44. Vargas M.R., Pehar M., Diaz Amarilla P.J., Beckman J.S., Barbeito L. Transcriptional profile of primary astrocytes expressing ALS linked mutant SOD1. J Neurosci Res 2008, 86:3515-3525.
45. Graeber M.B., Streit W.J. Microglia: biology and pathology. Acta Neuropathol 2010, 119:89-105.
46. Goldmann T., Prinz M. Role of microglia in CNS autoinmmunity. Clin Dev Immunol 2013, 2013:208093. 10.1155/2013/208093.
47. Rossi D., Brambilla L., Valori C.F., et al. Focal degeneration of astrocytes in amyotrophic lateral sclerosis. Cell Death Differ 2008, 15:1691-1700.
48. Rossi D., Volterra A. Astrocytic dysfunction: insights on the role in neurodegeneration. Brain Res Bull 2009, 80:224-232.
49. Yang W.W., Sidman R.L., Taksir T.V., et al. Relationship between neuropathology and disease progression in the SOD1 (G93A) ALS mouse. Exp Neurol 2011, 227:287-295.
50. Papadimitriou D., Le Verche V., Jacquier A., Burcin I., Przedborski S., Diane B. Inflammation in ALS and SMA: sorting out the good from devil. Neurobiol Dis 2010, 37:493-502.
51. Zhao W., Beers D.R., Henkel J.S., et al. Extracellular mutant SOD1 induces microglial mediated motoneuron injury. Glia 2010, 15:231-243.
52. Rosenmann H.I., Meiner Z. Frontotemporal dementia: clinical features, genetics, pathogenesis and treatment. Harefuah 2013, 152:661-666.
53. Kersaitis C., Halliday G.M., Kril J.J. Regional and cellular pathology in frontotemporal dementia: relationship to stage of disease in cases with and without Pick bodies. Acta Neuropathol 2004, 108:515-523.
54. Broe M., Kril J., Hallidal G.M. Astrocytic degeneration relates to the severity of disease in frontotemporal dementia. Brain 2004, 127:2214-2220.
55. Yin F., Dumont M., Banerjee R., et al. Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. FASEB J 2010, 24:4639-4647.
56. Verkhratsky A., Olabarria M., Noristani H.N., Yeh C.Y., Rodriguez J.J. Astrocytes in Alzheimer's disease. Neurotherapeutics 2010, 7:399-412.
57. Rodriguez J.J., Verkhratsky A. Neuroglial roots of neurodegenerative diseases?. Mol Neurobiol 2011, 43:87-96.
58. Olavarria M., Noristani H.N., Verkhratsky A., Rodriguez J.J. Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease. Glia 2010, 58:831-838.
59. Yeh C.Y., Vadhwana B., Verkhratsky A., Rodriguez J.J. Early astrocytic atrophy in the entorhinal cortex of a triple transgenic animal model of Alzheimer's disease. ASN Neuro 2011, 3:271-279.
60. Zilka N., Ferencik M., Hulin I. Neuroinflammation in Alzheimer's disease: protector or promoter?. Bratisi Lek Listy 2006, 107:374-383.
61. Weisman D., Hakimian E., Ho G.J. Interleukins, inflammation and mechanisms of Alzheimer's disease. Vitam Horm 2006, 74:505-530.
62. Halliday G.M., Stevens C.H. Glia: initiators and progressors of pathology in Parkinson's disease. Mov Disord 2011, 26:6-17.
63. McGann J.C., Lioy D.T., Nabdel G. Astrocytes conspire with neurons during progression of neurological diseases. Curr Opin Neurobiol 2012, 22:550-558.
64. Braak H., Sastre M., Del Tredici K. Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease. ActaNeuropathol 2007, 114:231-241.
65. More S.V., Kumar H., Kim I.S., Song S.Y., Choi D.K. Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson's disease. Mediators Inflamm 2013, 2013:952375. 10.1155/2013/952375.
66. Schmidt S., Linnartz B., Mendritzki S., et al. Genetic mouse models for Parkinson's disease display severe pathology in glial cell mitochondria. Hum Mol Genet 2011, 20:1197-1211.
67. Mendritzki S., Scmidt S., Sczepan T., et al. Spinal cord pathology in alpha-synuclein transgenic mice. Parkinsons Dis 2010, 375462. 10.40612010/375462.
68. Gu X.L., Long C.X., Sun L., Xie C., Lin X., Cai H. Astrocytic expression of Parkinson's disease-related A53T α-synuclein causes neurodegeneration in mice. Mol Brain 2010, 3:12. 10.1186/1756-6606-3-12.
69. Malek N., Swallow D., Grosset K.A., Anichtchik O., Spillantini M., Grosset D.G. Alpha synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease - a systematic review. Acta Neurol Scand 2014, 130:59-72.
70. Oliveira J.M. Mitochondrial bioenergetics and dynamic in Huntington's disease: tripartite synapses and selective striatal degeneration. J Bioenerg Biomembr 2010, 42:227-234.
71. Cowan C.M., Raymond L.A. Selective neuronal degeneration in Huntington's disease. Curr Top Dev Biol 2006, 75:25-71.
72. Ilieva H., Polymenidou M., Cleveland D.W. Non cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol 2008, 187:761-772.
73. Bradford J., Shin J.Y., Roberts M., Wang C.E., Li X.J., Li S. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci USA 2009, 106:22480-22485.
74. Faideau M., Kim J., Cormier K., et al. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects. Hum Mol Genet 2010, 19:3053-3067.
75. Shin J.Y., Fang Z.H., Yu Z.X., Wang C.E., Li S.H., Li X.J. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol 2005, 171:1001-1012.
76. Hsiao H.Y., Chern Y. Targeting glial cells to elucidate the pathogenesis of Huntington's disease. Mol Neurobiol 2010, 41:248-255.
77. Gu X., Andre V.M., Cepeda C., et al. Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease. Mol Neurodegener 2007, 2:8. 10.1186/1750-1326-2-8.
78. Sapp E., Kegel K.B., Aronin N., et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 2001, 60:161-172.
79. Pavese N., Gerhard A., Tai Y.F., et al. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 2006, 66:1638-1643.
80. Cicchetti F., Lacroix S., Cisbani C., et al. Mutant huntingtin is present in neuronal grafts in Huntington's disease patients. Ann Neurol 2014, 76:31-42.
81. Custer S.K., Garden G.A., Gill N., et al. Bergmann glia expression of polyglutamine-expanded ataxin-7 produces neurodegeneration by impairing glutamate transport. Nat Neurosci 2006, 9:1302-1311.
82. Garden G.A., Libby R.T., Fu Y.H., et al. Polyglutamine expanded ataxin 7 promotes non cell autonomous Purkinge cell degeneration and displays proteolitic cleavage in ataxin transgenic mice. J Neurosci 2002, 22:4897-4905.
83. Ravits J., Paul P., Jorg C. Focality of upper and lower motoneuron degeneration at the clinical onset of ALS. Neurology 2007, 68:1571-1575.
84. Ravits J., Laurie P., Fann Y., Moore D.H. Implications of ALS focality: rostral-caudal distribution of lower motor neuron loss post-mortem. Neurology 2007, 68:1576-1582.
85. Gargiullo Monachelli G.M., Janota F., Bettini M., Shoesith C.L., Stron M.J., Sica R.E. Regional spread pattern predicts survival in patients with amyotrophic lateral sclerosis. Eur J Neurol 2012, 19:834-841.
86. Yoshida T., Nakagawa M. Clinical aspects and pathology of Alexander disease, and morphological and functional alteration of astrocytes induced by GFAP mutation. Neuropathology 2012, 32:449-456.
87. Alfahad T., Nath A. Retroviruses and amyotrophic lateral sclerosis. Antiviral Res 2013, 99:180-187.
88. Prusiner S.B. Biology and genetics of prion causing neurodegeneration. Annu Rev Genet 2013, 47:601-623.
89. Kantarci K. Proton MRS in mild cognitive impairment. J Magn Reson Imaging 2013, 37:770-777.